Table 2.
Clinical outcomes at 1-month follow-up between the two groups
| Items | Aspirin group (n = 139) | No-aspirin group (n = 249) | χ2 | P |
|---|---|---|---|---|
| Hemorrhage, n (%) | 1 (0.8) | 3 (1.3) | 0.005 | 0.944 |
| BARC type 2 | 1 (0.8) | 1 (0.4) | 0.102 | 0.749 |
| BARC type 5 | 0 (0.0) | 2 (0.9) | 0.102 | 0.749 |
| Death, n (%) | 5 (3.6) | 7 (2.8) | 0.184 | 0.668 |
| Cardiac death | 1 (0.8) | 3 (1.3) | 0.005 | 0.944 |
| Aortic death | 2 (1.5) | 2 (0.9) | 0.005 | 0.944 |
| Other causes of death | 2 (1.5) | 2 (0.9) | 0.005 | 0.944 |
| Endoleak, n (%) | 3 (2.3) | 5 (2.2) | 0.074 | 0.785 |
| Recurrent dissection, n (%) | 3 (2.3) | 5 (2.2) | 0.074 | 0.785 |
| Myocardial infarction, n (%) | 1 (0.8) | 1 (0.4) | 0.102 | 0.749 |
| Cerebral infarction | 0 | 0 | – | – |
BARC: Bleeding Academic Research Consortium; –: Not applicable.